Floatz logo

HUMAN IGG1 ANTI-IL-15 MONOCLONAL ANTIBODY

In-situ Small Bowel T-cell Lymphoma

Amgenmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the In-situ Small Bowel T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Fludarabine
Case Comprehensive Cancer Center
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2BBB
Cyclophosphamide
University of Chicago
Phase 2BBB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
DEXAMETHASONE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

HUMAN IGG1 ANTI-IL-15 MONOCLONAL ANTIBODY is also rated in:

celiac diseaseDormant
B
Indicative ·
62 / 100
View asset →
refractory celiac diseaseDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →